274 related articles for article (PubMed ID: 31747911)
1. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis.
Guo X; Zhao F; Ma X; Shen G; Ren D; Zheng F; Du F; Wang Z; Ahmad R; Yuan X; Zhao J; Zhao J
BMC Cancer; 2019 Nov; 19(1):1125. PubMed ID: 31747911
[TBL] [Abstract][Full Text] [Related]
2. Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis.
Mohammad NH; ter Veer E; Ngai L; Mali R; van Oijen MG; van Laarhoven HW
Cancer Metastasis Rev; 2015 Sep; 34(3):429-41. PubMed ID: 26267802
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer.
Wang S; Wang Q; Tian J; Zhou Z; Jiao L; Fu Y; Chen S; Zhang J; Xu L
J Int Med Res; 2015 Dec; 43(6):727-37. PubMed ID: 26438014
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis.
Cho YH; Yoon SY; Kim SN
Cancer Res Treat; 2017 Jan; 49(1):255-262. PubMed ID: 27188198
[TBL] [Abstract][Full Text] [Related]
5. Doublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled Trials.
Zhang Y; Ma B; Huang XT; Li YS; Wang Y; Liu ZL
Medicine (Baltimore); 2016 Feb; 95(8):e2792. PubMed ID: 26937908
[TBL] [Abstract][Full Text] [Related]
6. S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis.
Yang J; Zhou Y; Min K; Yao Q; Xu CN
World J Gastroenterol; 2014 Sep; 20(33):11886-93. PubMed ID: 25206296
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.
Ter Veer E; Mohammad NH; Lodder P; Ngai LL; Samaan M; van Oijen MG; van Laarhoven HW
Gastric Cancer; 2016 Jul; 19(3):696-712. PubMed ID: 26754295
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials.
Huang J; Zhao Y; Xu Y; Zhu Y; Huang J; Liu Y; Zhao L; Li Z; Liu H; Wang QL; Qi X
Oncotarget; 2016 Jun; 7(23):34824-31. PubMed ID: 27166187
[TBL] [Abstract][Full Text] [Related]
10. Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature.
Ter Veer E; Haj Mohammad N; van Valkenhoef G; Ngai LL; Mali RM; van Oijen MG; van Laarhoven HW
Cancer Metastasis Rev; 2016 Sep; 35(3):439-56. PubMed ID: 27417221
[TBL] [Abstract][Full Text] [Related]
11. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
Lung; 2012 Oct; 190(5):477-85. PubMed ID: 22711060
[TBL] [Abstract][Full Text] [Related]
12. S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
He MM; Wu WJ; Wang F; Wang ZQ; Zhang DS; Luo HY; Qiu MZ; Wang FH; Ren C; Zeng ZL; Xu RH
PLoS One; 2013; 8(12):e82798. PubMed ID: 24349363
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
Zhong A; Xiong X; Shi M; Xu H
Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
[TBL] [Abstract][Full Text] [Related]
14. S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials.
Li DH; Pan ZK; Ye F; An HX; Wu JX
Tumour Biol; 2014 Aug; 35(8):8201-8. PubMed ID: 24850178
[TBL] [Abstract][Full Text] [Related]
15. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer.
Luo HQ; Han L; Jiang Y
Asian Pac J Cancer Prev; 2014; 15(13):5343-8. PubMed ID: 25040999
[TBL] [Abstract][Full Text] [Related]
17. Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis.
Yang XQ; Li CY; Xu MF; Zhao H; Wang D
BMC Cancer; 2015 Dec; 15():949. PubMed ID: 26673747
[TBL] [Abstract][Full Text] [Related]
18. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Riemsma R; Forbes CA; Amonkar MM; Lykopoulos K; Diaz JR; Kleijnen J; Rea DW
Curr Med Res Opin; 2012 Aug; 28(8):1263-79. PubMed ID: 22738819
[TBL] [Abstract][Full Text] [Related]
20. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]